Effects of Canagliflozin on Intravascular Volume and Hemodynamics
Status:
Withdrawn
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
RESEARCH HYPOTHESIS
- In subjects with T2DM and HF, effect of canagliflozin will be superior to placebo for
the change from baseline in PCWP after a single dose (6 hours post-dose) and after 4
weeks.
- Treatment with canagliflozin will be well tolerated over 4 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Devjit Tripathy The University of Texas Health Science Center at San Antonio